Search

Your search keyword '"Valim, Valéria"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Valim, Valéria" Remove constraint Author: "Valim, Valéria" Publication Year Range Last 3 years Remove constraint Publication Year Range: Last 3 years
43 results on '"Valim, Valéria"'

Search Results

2. Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases

3. Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose

4. Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients

5. Brazilian version of the “Primary Sjögren’s Syndrome - Quality of Life questionnaire (PSS-QoL)”: translation, cross-cultural adaptation and validation

6. Predictors of Hospitalization in Breakthrough COVID-19 among Fully Vaccinated Individuals with Immune-Mediated Rheumatic Diseases: Data from SAFER-Study.

7. Brazilian version of the "Primary Sjögren's Syndrome - Quality of Life questionnaire (PSS-QoL)": translation, cross-cultural adaptation and validation.

8. Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2

9. Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination

10. The effect of antimalarials on the safety and persistence of treatment with biologic agents or Janus kinase inhibitors in rheumatoid arthritis.

11. EVENTOS ADVERSOS À 3ª DOSE DAS VACINAS ASTRAZENECA E PFIZER EM UMA COORTE DE TRABALHADORES DA SAÚDE

12. Panoramic snapshot of serum soluble mediator interplay in pregnant women with convalescent COVID-19: an exploratory study

13. Clinical risk factors for predicting anti-Sars-CoV-2 antibody immunoreactivity duration after mild COVID-19 infection

14. CARDIOVASCULAR RISK IN SJÖGREN S DISEASE FROM THE BRAZILIAN SJÖGREN S DISEASE REGISTRY (REBRAS)

17. POSITIVITY OF ANTI-LA/SSB ANTIBODIES IN SJÖGREN S DISEASE IS ASSOCIATED WITH EXTRA-GLANDULAR SYSTEMIC MANIFESTATION: RESULTS FROM THE THE BRAZILIAN SJÖGREN S DISEASE REGISTRY (REBRAS)

18. THE EFFECT OF ANTIMALARIALS ON THE RISK AND SEVERITY OF BACTERIAL, VIRAL, FUNGAL AND SYSTEMIC SPECIFIC INFECTIONS IN RHEUMATOID ARTHRITIS

20. EFFECTS OF MANUAL VAGUS NERVE THERAPY COMBINED WITH TRANSCRANIAL DIRECT CURRENT STIMULATION ON PAIN IN WOMEN WITH FIBROMYALGIA: A RANDOMIZED CONTROLLED TRIAL

22. Unbalanced networks and disturbed kinetics of serum soluble mediators associated with distinct disease outcomes in severe COVID-19 patients

23. Comparison Of The Immunogenicity Among Covid-19 Vaccines Chadox1, Coronavac Or Bnt162b2 In Systemic Lupus Erythematosus (Sle): A Prospective Cohort

24. ARTICULAR SYSTEMIC DISEASE ACTIVITY AT DIAGNOSIS IS ASSOCIATED WITH DAMAGE, FATIGUE, PAIN AND DRYNESS OVER TIME IN PRIMARY SJÖGREN’S SYNDROME

25. SAFETY OF THE CORONAVAC AND CHADOX 1 COVID-19 VACCINES IN PATIENTS WITH RHEUMATOID ARTHRITIS: DATA FROM SAFER STUDY

26. FATIGUE IS ASSOCIATED WITH SYMPTOMS, DEPRESSION, ANXIETY, SLEEPINESS AND DISEASE ACTIVITY IN PRIMARY SJÖGREN’S SYNDROME

27. Safety assessment of BNT162b2, SinoVac and ChAdOx1 vaccines in Systemic Lupus Erythematosus patients – Data from SAFER Study

28. DIFFICULT ACCESS TO PREVENTION AND DETECTION MEASURES OF COVID-19 IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

29. VALIDITY AND RELIABILITY OF THE BRAZILIAN VERSION OF THE PRIMARY SJÖGREN’S SYNDROME QUESTIONNAIRE

30. IMMUNOGENICITY AND SAFETY OF THE CHADOX-1 COVID-19 VACCINE IN PATIENTS WITH AUTOIMMUNE DISEASES AND HEALTHY CONTROLS: DATA FROM SAFER STUDY

31. Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis

32. REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)

33. EVENTOS ADVERSOS ÀS VACINAS CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES DA SAÚDE

34. REATIVIDADE VACINAL E DURAÇÃO DE RESPOSTA IMUNE DA CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES

35. EFETIVIDADE, IMUNOGENICIDADE E SEGURANÇA DA MEIA DOSE DA VACINA CHADOX1 NCOV-19 CONTRA SARS-COV2 (PROJETO VIANA)

37. Safety of the Methotrexate–leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil)

38. Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence

39. Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium

40. Clinical risk factors for predicting anti-Sars-Cov-2 antibody immunoreactivity duration after mild COVID-19 infection.

41. Safety of the Methotrexate-leflunomide Combination in Rheumatoid Arthritis: Results of a Multicentric, Registry-based, Cohort Study (BiobadaBrasil).

42. Epidemiologic profile of juvenile-onset compared to adult-onset spondyloarthritis in a large Brazilian cohort

43. Effectiveness, safety, and immunogenicity of half dose ChAdOx1 nCoV-19 COVID-19 Vaccine: Viana project.

Catalog

Books, media, physical & digital resources